Heterocyclic Compounds

Matches 1,551 - 1,600 out of 37,117	< 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 >

Document	Document Title
WO/2022/263801A1	PROCESS FOR PREPARING PEXIDARTINIB The present invention relates to a process for the preparation of a compound of formula (VI), or a salt or derivative thereof, comprising reacting a compound of formula (V) with a compound of formula (IX) wherein R2, R4, R5 and Z are as ...
WO/2022/266112A1	ALSTONINE DERIVATIVES AND SALTS THEREOF The present disclosure is concerned with alstonine, alstonine analogs, and salts thereof for the treatment of various disorders where changes in 5-HT2A/5-HT2C receptor signaling and/or dopamine transporter activity may be beneficial such...
WO/2022/266425A1	3-CYANO-QUINOLINE DERIVATIVES AND USES THEREOF The present disclosure relates to compounds of Formula (I): and pharmaceutically acceptable salts and stereoisomers thereof, useful in the treatment of cancers associated with ErbB oncogenic activity, including methods of preparing the c...
WO/2022/262854A1	CLY SERIES COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF DRUGS Disclosed in the present invention are a CLY series compound, a preparation method therefor and the use thereof in the preparation of drugs. The CLY series compound is a compound with a structure of formula I, a tautomer thereof, a solva...
WO/2022/263548A1	3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS The present invention relates to certain 3-substituted 1 H-pyrrolo[2,3-b]pyridine compounds of the formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment or prevention of a disease or medic...
WO/2022/261777A1	USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS FOR TREATING CANCER Disclosed are methods of treating a cancer and of inducing cell death in an aberrant cancel cell in a subject using a combination of an ATR inhibitor and PARP inhibitor, wherein the PARP inhibitor may be a compound of formula (III) or (I...
WO/2022/262838A1	DEUTERATED COMPOUNDS USEFUL AS KRAS G12D INHIBITORS Provided are deuterated compounds of Formula (I), or Formula (I'), or a salt thereof, wherein at least one of R 1 to R 6 is D (Deuterium atom), and X 0, Y, and R is defined herein. Also provided are methods of using such compounds to mod...
WO/2022/262244A1	UREA CO-CRYSTAL OF APIXABAN, AND PREPARATION METHOD THEREFOR A urea co-crystal form A of apixaban, and a preparation method therefor. The urea co-crystal A has high physical and chemical stability, crystal form stability and drug forming stability, better solubility, and higher bioavailability. Th...
WO/2022/266193A1	BICYCLIC COMPOUNDS Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
WO/2022/266236A1	METHODS AND COMPOSITIONS FOR TARGETING PD-L1 The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmace...
WO/2022/262784A1	IDH MUTANT INHIBITOR AND USE THEREOF An IDH mutant inhibitor and a use thereof. Specifically, the present invention relates to a compound represented by general formula (1) and a preparation method therefor; and a use of the compound represented by general formula (1), as w...
WO/2022/257960A1	BICYCLIC COMPOUND FOR THE TREATMENT OF EP2 AND EP4 RECEPTOR-MEDIATED DISEASES A bicyclic compound represented by formula I, and tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts, or prodrugs thereof; the bicyclic compound can be used for the treatment of EP2 and EP4 receptor-mediated ...
WO/2022/257845A1	CRYSTAL FORM OF TOLEBRUTINIB, PREPARATION METHOD THEREFOR AND USE THEREOF The present invention relates to a new crystal form of tolebrutinib (hereinafter referred to as "compound I"), a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of same in the preparatio...
WO/2022/257047A1	DIAZASPIROBICYLIC COMPOUNDS AS PROTEIN-PROTEIN INTERACTION INHIBITORS AND APPLICATIONS THEREOF The present disclosure provides diazaspirobicylic compounds as protein-protein interaction inhibitors and applications thereof. Specifically, the present disclosure provides a compound of formula I or pharmaceutically acceptable salts or...
WO/2022/258044A1	PYRROLOPYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Provided are a pyrrolopyridinone compound as represented by formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutical preparation, a pharmaceutical composition and the use of the compound, wherein the compound can ...
WO/2022/259993A1	PPARα TRANSCRIPTION ACTIVATOR AND PHARMACEUTICAL USE THEREOF The purpose of the present invention is to provide a novel PPARα transcription activator.　The present invention relates to a compound given by formula (I) or a salt thereof [The symbols in the formula are as described in the Descripti...
WO/2022/257894A1	P300 INHIBITOR AND PHARMACEUTICAL USE THEREOF A compound of formula (I), a tautomer, a deuterated product, or pharmacologically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as a drug for treating a ca...
WO/2022/257568A1	AZAINDOLE PYRIMIDINAMINE HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed in the present invention are an azaindole pyrimidinamine heterocyclic compound as shown in formula (S), and a preparation method therefor and the use thereof. The compound of the present invention can inhibit the malignant prol...
WO/2022/258023A1	COMPOUND AS CDK KINASE INHIBITOR AND USE THEREOF The present invention relates to a compound as a CDK kinase inhibitor and the use thereof. Specifically, the compound of the present invention has a structure as shown in formula (I), wherein the definitions of each group and each substi...
WO/2022/258007A1	SALT AND CRYSTAL FORM OF PYRAZOLE-CONTAINING POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF An acid salt and a crystal form of a pyrazole-containing polycyclic derivative represented by formula (I-a), and a preparation method therefor, a pharmaceutical composition containing a therapeutically effective amount of the crystal for...
WO/2022/261473A1	PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS The application relates to compounds of Formula (I) and (III), their pharmaceutically acceptable salts, and their pharmaceutical compositions. The compounds are potent inhibitors of the main protease (Mpro) of severe acute respiratory sy...
WO/2022/258052A1	HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF Disclosed is a heterocyclic lactam compound or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, as represented in formula (I), wherein the compounds have an inhibitory effect on RIPK1 and the definition of ea...
WO/2022/257581A1	A CLASS OF IMIDAZOLIDINOPYRIMIDONE COMPOUNDS AND USE THEREOF IN TREATMENT OF HSCLPP-MEDIATED DISEASES The present invention relates to the use of a class of imidazolidinopyrimidone compounds, or a pharmaceutically acceptable salt, a hydrate or a crystal form thereof in the treatment of human caseinolytic protease P (HsClpP) mediated dise...
WO/2022/261404A1	METHODS AND COMPOSITIONS FOR LIPID FORMULATION OF LIPOPHILIC SMALL MOLECULE THERAPIES OF THE HETEROCYCLIC TYPE Methods and compositions for delivery of a therapeutic useful for e.g., neuron regeneration, neuroprotection, and/or slowing disease progression. Treatment of diseases and conditions characterized by neurodegeneration.
WO/2022/261633A1	NOVEL SALTS AND CRYSTALS The disclosure provides new salts, crystals and co-crystal forms of particular substituted heterocycle fused gamma-carbolines, as described herein, together with methods of making and using them, and pharmaceutical compositions comprisin...
WO/2022/261159A1	TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
WO/2022/261160A1	TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
WO/2022/260441A1	PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS This invention relates to compounds which are microtubule associated serine/threonine-like kinase (MASTL) inhibitors and the use of the compounds in the treatment of diseases and medical conditions mediated by MASTL, for example in the t...
WO/2022/261210A1	KRAS MODULATORS AND USES THEREOF Provided herein are KRAS modulating compounds, such as compounds of formula (I) or pharmaceutically acceptable salts, solvates, stereoisomers, atom labelled, or tautomers of any of the foregoing, useful for modulating KRAS GD12 and/or ot...
WO/2022/256808A1	COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR Provided herein is a combination therapy and methods of using such combination therapy to treat diseases or disorders associated with MAT2A and/or Type I PRMT.
WO/2022/253936A1	TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER. The invention relates to novel compounds having the general formula Ib wherein R1, R2, R3, R4, R5 and Z are as described herein, composition including the compounds and methods of using the compounds.
WO/2022/255915A1	PET RADIOTRACERS The compounds of the invention are ASEM analogs with different ortho- and para-substitutions that can be labelled with 3H and/or 11C to be used as PET radiotracers capable of binding to α7-nAChR both in vitro and in vivo in a subject bo...
WO/2022/256806A1	COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR Provided herein is a combination product comprising a methionine adenosyltransferase II alpha (MAT2A) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The combination product is useful for the treatmen...
WO/2022/251971A1	CRYSTALLINE FORMS, COMPOSITIONS CONTAINING SAME, AND METHODS OF THEIR USE Disclosed are crystalline forms of the compound of the following structure (I): or a sulfate salt, a hemi-sulfate salt, or a hydrogen sulfate salt thereof, or a hydrate thereof. Also disclosed are sulfate salts, hemi-sulfate salts, and h...
WO/2022/255888A1	TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN A compound of formula (I) [MCL-1 ligand moiety] - [linker] - [ligase ligand moiety] (I) or a salt, solvate, hydrate, isomer or prodrug thereof, wherein [MCL-1 ligand moiety] is a compound of Formula (A), Formula (B) or Formula (C) and it...
WO/2022/253242A1	METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR The present invention provides a methionine adenosyltransferase 2A inhibitor. The structure of the methionine adenosyltransferase 2A inhibitor is as represented by general formula (I), and the definitions of substituents are as described...
WO/2022/253294A1	PYRIDONE COMPOUND HAVING INTEGRASE INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF The present disclosure provides a pyridone compound having integrase inhibitory activity and a pharmaceutical use thereof. Specifically, the present disclosure provides a compound having a structure shown as formula I or a pharmaceutical...
WO/2022/256702A1	SUBSTITUTED TETRAHYDROFURAN-2-CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS Compounds of formula I and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and m...
WO/2022/253713A1	TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN A compound of formula (I); [MCL-1 ligand moiety] - [linker] - [ligase ligand moiety] (I); or a salt, solvate, hydrate, isomer or prodrug thereof, wherein [MCL-1 ligand moiety] is a compound of Formula (A), Formula (B) or Formula (C), and...
WO/2022/253327A1	PREPARATION AND USE OF COMPOUND HAVING IMMUNOMODULATORY FUNCTION Disclosed are a preparation method and use of a compound having an immunomodulatory function. Specifically, disclosed is a compound having the structure as shown in formula I, wherein the definition of each group is as described in the s...
WO/2022/254362A1	3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND MEDICAL USES THEREOF The application relates to compounds of formula (I), pharmaceutical compositions comprising them and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and ...
WO/2022/255399A1	G9A INHIBITOR The present invention pertains to a compound represented by general formula (I) or a pharmacologically acceptable salt thereof and a pharmaceutical use thereof, for example, a pharmaceutical composition that is to be used for preventing ...
WO/2022/216971A9	PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
WO/2022/253311A1	HPK1 INHIBITOR AND USE THEREOF A compound as represented by formula I as an HPK1 inhibitor, a pharmaceutical composition comprising the compound, and the use of the compound in the preparation of a drug.
WO/2022/256459A1	KRAS MODULATORS AND USES THEREOF Provided herein are KRAS modulating compounds, such as compounds of Formula (I), (II), (III), or (X), or pharmaceutically acceptable salts, solvates, stereoisomers, atom labelled, or tautomers of any of the foregoing, useful for modulati...
WO/2022/253259A1	FUSED HETEROCYCLIC DERIVATIVES The application describes fused heterocycle derivative compounds, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases associated with HBV inf...
WO/2022/254218A1	PROCESSES FOR THE PREPARATION OF INHIBITORY COMPOUNDS The present invention relates to processes for the preparation of certain compounds that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) activity, and their synthethic intermediates.
WO/2022/253313A1	PHOSPHATE OF TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE COMPOUND A phosphate compound of a trifluoromethyl-substituted sulfonamide compound for selectively inhibiting anti-apoptotic protein BCL-2, a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof ...
WO/2022/254464A1	SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUNDS AS METALLO-BETA-LACTAMASE INHIBITORS The invention relates to substituted tricyclic heterocyclic compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions wherein, R1, R2, R3, R4, R5, R6, R7, R8, R9, 5 R10, R11, X1, X2, X3, X4, X5 a...
WO/2022/253255A1	FUSED HETEROCYCLIC DERIVATIVES The application describes fused heterocycle derivative compounds, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases associated with HBV inf...

Matches 1,551 - 1,600 out of 37,117	< 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 >